Mark T. CarperMark T.Carper

A global rare disease biopharmaceutical manufacturer in connection with its receipt of a U.S. Department of Justice subpoena for production of documents pertaining to its marketing and promotion of a rare disease treatment, resulting in no civil or criminal penalties.

A multi-national medical device manufacturer in connection with their voluntary disclosures to the U.S. Department of Justice related to potential violations of the Foreign Corrupt Practices Act in multiple jurisdictions, resulting in no civil or criminal penalties.

A molecular diagnostics company before a state department of health and conducted an internal investigation related to whistleblower allegations of Medicare fraud and Anti-Kickback Statute violations.

Conducted U.S. healthcare and global anti-bribery and anti-corruption-focused risk assessments and due diligence on behalf of multi-national medical device, biologics, molecular diagnostics and private equity portfolio companies.

Drafted and revised global policies, procedures and trainings on numerous topics, including corporate governance, internal investigations, health care professional interactions, company training and events, third-party funding, patient support and distributor management.